448 Matching Annotations
  1. Aug 2022
    1. Lucas, C., Vogels, C. B. F., Yildirim, I., Rothman, J. E., Lu, P., Monteiro, V., Gelhausen, J. R., Campbell, M., Silva, J., Tabachikova, A., Peña-Hernandez, M. A., Muenker, M. C., Breban, M. I., Fauver, J. R., Mohanty, S., Huang, J., Shaw, A. C., Ko, A. I., Omer, S. B., … Iwasaki, A. (2021). Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04085-y

    1. Krause, P. R., Fleming, T. R., Peto, R., Longini, I. M., Figueroa, J. P., Sterne, J. A. C., Cravioto, A., Rees, H., Higgins, J. P. T., Boutron, I., Pan, H., Gruber, M. F., Arora, N., Kazi, F., Gaspar, R., Swaminathan, S., Ryan, M. J., & Henao-Restrepo, A.-M. (2021). Considerations in boosting COVID-19 vaccine immune responses. The Lancet, 4. https://doi.org/10.1016/S0140-6736(21)02046-8

  2. May 2022
  3. Apr 2022
    1. Tom Wenseleers. (2022, January 23). @HarrySpoelstra @trvrb @CorneliusRoemer @JosetteSchoenma BA.2 has a growth rate advantage over BA.1 of ca 0.11/day. That’s quite sizeable. If it would have the same short generation time as BA.1 of 2.2 days it would imply a ca.1.3x higher transmissibility, due to higher contagiousness or immune escape. Https://t.co/X8TcWJ4pXQ [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1485375883066101763

    1. Prof Francois Balloux [@BallouxFrancois]. (2021, December 9). This may have sounded somewhat naïve in early 2020, but by now, I would have expected that anyone with an interest in covid-19 might have acquired some basic notions in infectious disease epidemiology. 1/ [Tweet]. Twitter. https://twitter.com/BallouxFrancois/status/1469063480334561285

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. Paul Bieniasz [@PaulBieniasz]. (2021, December 12). It is time to discard the notion that two doses of mRNA means “fully vaccinated” It is time to discard the notion that prior SARS-CoV-2 infection means you don’t need to be vaccinated. [Tweet]. Twitter. https://twitter.com/PaulBieniasz/status/1470041859053563906

    1. Dr Nisreen Alwan 🌻. (2021, March 14). Exactly a year ago we wrote this letter in the Times. We were gobsmacked! We just didn’t understand what the government was basing all its decisions on including stopping testing and the herd immunity by natural infection stuff. We wanted to see the evidence backing them. [Tweet]. @Dr2NisreenAlwan. https://twitter.com/Dr2NisreenAlwan/status/1371168531669258242

  4. Mar 2022
    1. Mia Malan. (2021, November 25). [Thread] What is the potential impact of the new B.1.1.529 #COVID19 variant? @rjlessells: 1. It’s relatively simple to detect some B.1.1.529 cases, as it’s possible to use PCR tests to do this in some cases 2. B.1.1.529 = has many mutations across different parts of the virus https://t.co/ytktqLzJUi [Tweet]. @miamalan. https://twitter.com/miamalan/status/1463846528578109444

    1. george davey smith. (2021, December 28). Omicron is illustrating “herd immunity” as how it was introduced: A relative concept, that reduces the adverse outcome of infections within populations, not as an absolute threshold that stopped transmission; as @bmj_latest #covidunknowns webinar explains https://t.co/t8nPeL9V8r [Tweet]. @mendel_random. https://twitter.com/mendel_random/status/1475821583331700739

  5. Feb 2022
    1. Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradnik, J., Shirakawa, K., Suzuki, R., Kishimoto, M., Kosugi, Y., Kobiyama, K., Hara, T., Toyoda, M., Tanaka, Y. L., Butlertanaka, E. P., Shimizu, R., … Sato, K. (2022). Virological characteristics of SARS-CoV-2 BA.2 variant (p. 2022.02.14.480335). bioRxiv. https://doi.org/10.1101/2022.02.14.480335

    1. Peña-Hernández, M. A., Klein, J., Malik, A. A., Coppi, A., Kalinich, C., Vogels, C. B. F., Silva, J., Initiative, Y. S.-C.-2 G. S., Peaper, D. R., Landry, M.-L., Wilen, C., Grubaugh, N. D., Schulz, W., Omer, S. B., & Iwasaki, A. (2022). Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals (p. 2021.12.28.21268460). medRxiv. https://doi.org/10.1101/2021.12.28.21268460

    1. Afkhami, S., D’Agostino, M. R., Zhang, A., Stacey, H. D., Marzok, A., Kang, A., Singh, R., Bavananthasivam, J., Ye, G., Luo, X., Wang, F., Ang, J. C., Zganiacz, A., Sankar, U., Kazhdan, N., Koenig, J. F. E., Phelps, A., Gameiro, S. F., Tang, S., … Xing, Z. (2022). Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell, S0092867422001453. https://doi.org/10.1016/j.cell.2022.02.005

    1. Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488

  6. Jan 2022
    1. Tom Wenseleers. (2022, January 30). Seems that the second Omicron subvariant BA.2 may soon be about to cause cases to start rising again in South Africa... Or at least to stop the decline in new infections. Shows how fast immunity wanes & evolution can catch up. Https://t.co/3y4xqPgZ0L [Tweet]. @TWenseleers. https://twitter.com/TWenseleers/status/1487919837670219781

    1. Jennifer Cohn ✍🏻 📢. (2022, January 11). This chart says it all. If u got double vaccinated early on & are not yet boosted, ur effectively unvaccinated against Omicron infection. Thus, many adults & teens are effectively unvaccinated against infection. Kids got vaccinated recently & thus may be in a safer position. 1/ [Tweet]. @jennycohn1. https://twitter.com/jennycohn1/status/1481034404260581377

  7. Dec 2021
    1. A Marm Kilpatrick. (2021, November 24). How do we get broad immunity to SARS-CoV-2 that will protect against future variants? 2 studies (are there more?) suggest that vaccination followed by infection gives broader protection than infection followed by vaccination. @florian_krammer @profshanecrotty @GuptaR_lab https://t.co/rqdf6rE9ej [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1463391782742335491

    1. ReconfigBehSci on Twitter: “but it is not vaccinated people that are disproportionately filling up ICUs. For any government whose policy is guided by ICU capacity, limiting the transmission possibilities for the unvaccinated is now the point. It is frustrating to see someone continue to ignore this” / Twitter. (n.d.). Retrieved December 23, 2021, from https://twitter.com/SciBeh/status/1471088416246878211

    1. Jay Varma. (2021, December 16). Um, we’ve never seen this before in #NYC. Test positivity doubling in three days 12/9—3.9% 12/10—4.2% 12/11—6.4% 12/12—7.8% Note: Test % is only for PCR & NYC does more per capita daily than most places ~67K PCR/day + 19K [reported] antigen over past few days (1/2) https://t.co/PhxsZq55jn [Tweet]. @DrJayVarma. https://twitter.com/DrJayVarma/status/1471485885447389186

    1. Garcia-Beltran, W. F., Denis, K. J. S., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., Feldman, J., Gregory, D. J., Poznansky, M. C., Schmidt, A. G., Iafrate, A. J., Naranbhai, V., & Balazs, A. B. (2021). MRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant (p. 2021.12.14.21267755). https://doi.org/10.1101/2021.12.14.21267755

    1. Heitmann, J. S., Bilich, T., Tandler, C., Nelde, A., Maringer, Y., Marconato, M., Reusch, J., Jäger, S., Denk, M., Richter, M., Anton, L., Weber, L. M., Roerden, M., Bauer, J., Rieth, J., Wacker, M., Hörber, S., Peter, A., Meisner, C., … Walz, J. S. (2021). A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity. Nature, 1–9. https://doi.org/10.1038/s41586-021-04232-5

    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Rathna Murugesan, D., Koundinya Desiraju, B., Kshetrapal, P., Pandey, R., Scaria, V., Kumar Malik, P., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, S1473309921006800. https://doi.org/10.1016/S1473-3099(21)00680-0

  8. Nov 2021
    1. Thiruvengadam, R., Awasthi, A., Medigeshi, G., Bhattacharya, S., Mani, S., Sivasubbu, S., Shrivastava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., Kshetrapal, P., Pandey, R., Scaria, V., Malik, P. K., Taneja, J., Binayke, A., Vohra, T., Zaheer, A., Rathore, D., … Garg, P. K. (2021). Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00680-0

    1. It remains unclear whether the reduction in the neutralization sensitivity of the N501Y.V2 strain to vaccine-induced antibodies is enough to seriously reduce vaccine efficacy. First, mRNA vaccines also induce virus-specific helper T cells and cytotoxic T cells, both of which might be involved in protection against challenge. Also, the mRNA vaccines, in particular, induce such a strong NAb response that there could be enough “spare capacity” to deal with reductions in the sensitivity of the variant to NAbs. In other words, N501Y.V2 (and the related virus from Brazil) may be less sensitive to NAbs, but not to an extent that will cause widespread vaccine failure.

      Variants that show reduced sensitivity to NAbs don't necessarily mean mRNA vaccine failure

      New variants may emerge that show reduced sensitivity to NAbs.

      This may not result in vaccine failure because:

      1. The mRNA vaccines induce such a strong NAb response, there will be enough spare capacity to deal with the virus.
      2. The mRNA vaccines also induce other virus specific protection such as helper T cells and cytotoxic T cells, which may not be affected by the reduction in NAb sensitivity.
    1. Dhar, M. S., Marwal, R., VS, R., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Bhatheja, N., Divakar, M. K., … Rakshit, P. (n.d.). Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science, 0(0), eabj9932. https://doi.org/10.1126/science.abj9932

    1. Eliminating Covid-19 seemed theoretically possible, because the original 2002 SARS virus ultimately disappeared.

      Eliminating SARS-CoV-2 was deemed plausible, because SARS-CoV-1 had been eliminated.

    1. Dr Nisreen Alwan 🌻. (2021, October 30). Mass infection of kids with a virus less than 2 years old is not ethical, not moral, not scientifically evidenced, not socially just & medically risky. There’s no good argument for this. And no, boosting population immunity to protect the adults is not a valid argument. #Childism [Tweet]. @Dr2NisreenAlwan. https://twitter.com/Dr2NisreenAlwan/status/1454498829403922440

    1. Dr Daya Sharma 😷🥽💨🧼💉💉. (2021, October 30). Some of the UK JCVI deliberations are deeply disturbing, eg arguing against childhood vax so that they can get infected & boost immunity in adults. Also imply that vax doesn’t have an individual benefit! 🤯 How much of this warped thinking is present in Australia? #COVID19Aus https://t.co/o887d2etcW [Tweet]. @DrDayaSharma. https://twitter.com/DrDayaSharma/status/1454418003429183492

    1. Prof. Gavin Yamey MD MPH. (2021, October 30). “Circulation of COVID-19 in childhood could therefore periodically boost immunity in adults through exposure” When I say childhood vax ALSO benefits adults, folx say “you can’t use benefits to adults in your argument!” JCVI uses benefits to adults of letting kids get infected 👀 [Tweet]. @GYamey. https://twitter.com/GYamey/status/1454433823085715461

    1. Deepti Gurdasani. (2021, November 1). No- the statement explicitly talks about infection in children being a ‘booster’ to adults i.e. Children infecting adults to protect them against... Infection!🤔 I don’t think there’s any level of cognitive gymnastics that could justify this or make sense of it. [Tweet]. @dgurdasani1. https://twitter.com/dgurdasani1/status/1455106192112500736

  9. Oct 2021
    1. Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., … Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 6197. https://doi.org/10.1038/s41467-021-26499-y

    1. Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano, E., Abbiento, V., Benincasa, L., Giglioli, G., De Santi, C., Fabbiani, M., Rancan, I., Tumbarello, M., Montagnani, F., Sala, C., Montomoli, E., & Rappuoli, R. (2021). Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature, 1–7. https://doi.org/10.1038/s41586-021-04117-7

    1. Hulme, W. J., Williamson, E. J., Green, A., Bhaskaran, K., McDonald, H. I., Rentsch, C. T., Schultze, A., Tazare, J., Curtis, H. J., Walker, A. J., Tomlinson, L., Palmer, T., Horne, E., MacKenna, B., Morton, C. E., Mehrkar, A., Fisher, L., Bacon, S., Evans, D., … Goldacre, B. (2021). Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: A cohort study using OpenSAFELY [Preprint]. Epidemiology. https://doi.org/10.1101/2021.10.13.21264937

    1. Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., Rubin, C., Freedman, L., Kreiss, Y., & Regev-Yochay, G. (2021). Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2114583

  10. Sep 2021
    1. Michael Mina on Twitter: “With all the news of vaccines & immunity, did you know measles infections destroy immunity and cause ‘Immune Amnesia’, increasing risk of all other infections Our research in ‘15 & ‘19 discovered this & the abbreviated story is written up nicely here: 1/ https://t.co/t5DKoQljxM” / Twitter. (n.d.). Retrieved September 7, 2021, from https://twitter.com/michaelmina_lab/status/1435037668027641861

    1. Kraemer, M. U. G., Hill, V., Ruis, C., Dellicour, S., Bajaj, S., McCrone, J. T., Baele, G., Parag, K. V., Battle, A. L., Gutierrez, B., Jackson, B., Colquhoun, R., O’Toole, Á., Klein, B., Vespignani, A., COVID-19 Genomics UK (COG-UK) Consortium‡, Volz, E., Faria, N. R., Aanensen, D. M., … Pybus, O. G. (2021). Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence. Science, 373(6557), 889–895. https://doi.org/10.1126/science.abj0113

    1. David Dowdy on Twitter: “@NEJM joining the waning immunity debate. I’m going to push back a bit. Data from @UCSDHealth of vax effectiveness in health workers: 94% in June, 65% in July. Interpreted as ‘likely to be due to...delta and waning immunity over time, compounded by end of masking requirements.’ https://t.co/flDOfBbTs7” / Twitter. (n.d.). Retrieved September 2, 2021, from https://twitter.com/davidwdowdy/status/1433254675915157504?s=20

  11. Aug 2021
    1. Liu, Y., Arase, N., Kishikawa, J., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., Jin, H., Kishida, K., Nakai, W., Kohyama, M., Nakagawa, A., Yamagishi, Y., Nakagami, H., Kumanogoh, A., Matsuura, Y., … Arase, H. (2021). The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (p. 2021.08.22.457114). https://doi.org/10.1101/2021.08.22.457114

    1. (2) David Fisman on Twitter: “Here’s some really simple modeling that hopefully will help provide some insight into why having a large, unvaccinated minority in Ontario is a problem for the population as a whole.” / Twitter. (n.d.). Retrieved August 23, 2021, from https://twitter.com/DFisman/status/1427940663925092354

    1. Kai Kupferschmidt on Twitter: “One of the most important things I was looking for in reporting on #SARSCoV2 evolution was a way of making sense of all the virus variants, putting them in some framework. And one of the most useful things I found for that is this antigenic map. It’s worth explaining a bit: Https://t.co/miO8Kh9w9e” / Twitter. (n.d.). Retrieved August 22, 2021, from https://twitter.com/kakape/status/1428650961652916230?s=20

    1. (((Howard Forman))). (2021, July 26). ‘Among those aged 60-plus, early vaccinators are twice as likely to get infected. For those aged 40-59 early vaccinators are 2.1 times more vulnerable, and among under 39s they are 1.6 more likely to catch the coronavirus.’ https://timesofisrael.com/hmo-those-who-inoculated-early-twice-as-likely-to-catch-covid-as-later-adopters/ [Tweet]. @thehowie. https://twitter.com/thehowie/status/1419647827458789383